TL;DR
MedPage Today published a Nov. 15, 2026, roundup of eight quotes from clinicians, researchers and health leaders on medical and policy issues. The comments address opioid use for sickle cell disease pain, an American Diabetes Association boycott, a lawsuit alleging safety concerns about resmetirom, vaccine debate, prostate screening and other topics; the roundup does not independently resolve those disputes.
MedPage Today published an eight-quote roundup on Nov. 15, 2026, capturing comments from health professionals and advocates on issues ranging from opioids and sickle cell disease pain to an organizational boycott, vaccine debate and prostate cancer screening. The piece is a weekly collection of remarks, not a report resolving the medical or policy questions behind them.
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Among the comments, Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai said, “Opioids cause pain. Full stop,” while discussing opioid use to treat pain in people with sickle cell disease. The roundup offers no further detail about his remarks, the clinical evidence he was addressing or how his statement relates to decisions about individual patients.
Other quotes concerned disputes and institutional developments. Christian Kohler, who resigned as vice president of publications at the American Diabetes Association, said an ongoing boycott of the organization was “not a frivolous exercise for the boycotters.” At the annual Liver Meeting, David Goldberg, MD, referred to a whistleblower lawsuit alleging safety concerns about the metabolic dysfunction-associated steatohepatitis drug resmetirom, sold as Rezdiffra. The roundup does not report a finding on those allegations.
The remaining remarks touched on patient descriptions of brain fog, public understanding of autism, criticism of a delayed federal vaccine task force report, prostate screening guidance and Australian use of pregabalin. MedPage Today presented these as notable quotes; the short item provides limited supporting detail for each topic.
Eight Quotes, Several Active Debates
The roundup brings attention to conversations affecting clinical practice and public trust, but its format matters: a quotation records a speaker’s view, not a consensus statement or a new policy by itself. Readers should distinguish the speakers’ interpretations from established findings, especially where comments concern medication safety, vaccines or screening.
The sickle cell comment is particularly consequential because pain management involves real clinical decisions. The quote alone does not provide enough information to guide treatment or establish that opioids should or should not be used for a particular person. The other comments likewise point to debates that require fuller reporting, including the circumstances of the ADA boycott and the status of the allegations concerning Rezdiffra.
Products Worth Considering

LG UltraGear 32GX850A-B 32-inch 4K UHD OLED Gaming Monitor

Samsung Galaxy Tab A11+ 11-Inch Tablet, 6GB RAM, 128GB Storage, Expandable, Gray

Apple MacBook Air 15-inch Laptop with M5 Chip, 16GB Memory, 512GB SSD, Liquid Retina Display, and Touch ID (Midnight)
As an affiliate, we earn on qualifying purchases.
The Roundup’s Medical Backdrop
MedPage Today’s “What We Heard This Week” feature compiles quotations from its reporters’ coverage. The Nov. 15 item spans several separate developments rather than announcing one shared event. Its eight quotes cover sickle cell disease, the American Diabetes Association, liver disease, sleep disorders, autism beliefs, vaccine policy, prostate screening and pregabalin use in Australia.
The source names the speakers and, in brief, identifies the setting or issue behind each remark. It says Goldberg raised a whistleblower lawsuit alleging safety concerns about resmetirom, and that Mark Ashamalla, MD, discussed updates to American Cancer Society prostate screening guidelines. It also reports that a survey found roughly one in four U.S. adults believed myths about autism risk, without providing the survey’s methods or defining the myths in the short roundup.
““This is not a frivolous exercise for the boycotters.””
— Christian Kohler, former vice president of publications at the American Diabetes Association
Claims Need More Detail
The roundup does not provide the evidence or full discussion behind Glassberg’s statement on opioids, nor does it establish how the remark should be applied to sickle cell pain care. The resmetirom safety concerns are described as allegations in a whistleblower lawsuit; the item does not state whether they have been substantiated or give the drugmaker’s response.
Several other points also lack detail in the short feature. It does not identify the ADA boycott’s demands, specify the vaccine task force report’s contents or provide the survey methods behind the autism figure. The roundup says prostate screening guidelines were updated and that Australian pregabalin use showed signs of reversing, but gives no dates, numerical trends or underlying sources for those developments.
Follow the Underlying Developments
The article itself is a weekly recap and does not announce a next event or scheduled decision. Readers seeking updates will need to follow the separate proceedings and guidance it references: any response or findings related to the resmetirom lawsuit, developments in the ADA boycott, details of the federal vaccine task force report and the full prostate screening recommendations.
For the clinical topics, further reporting or primary guidance would be needed to explain the evidence and its limits. The Nov. 15 roundup records what speakers said; it does not provide a new treatment directive or settle the disputes raised.
Key Questions
What did MedPage Today publish?
It published a weekly roundup of eight notable health-sector quotes on Nov. 15, 2026, covering medical care, advocacy and public health.
Was the opioid quote new treatment guidance?
No. The item attributes the comment to Jeffrey Glassberg during a discussion of opioid use for sickle cell disease pain, but does not present it as a clinical guideline or offer enough detail to direct individual care.
Were the resmetirom safety concerns confirmed?
The roundup describes them as allegations in a whistleblower lawsuit. It does not report whether the allegations were substantiated or provide the drugmaker’s response.
What other issues did the quotes address?
The comments also concerned an American Diabetes Association boycott, brain fog in sleep disorders, autism-risk beliefs, a federal vaccine task force report, prostate screening updates and pregabalin use in Australia.
Source: medpagetoday.com
